Encap licenses UK pharmacy school's colon drug delivery technology
This article was originally published in Scrip
A new colonic drug delivery system, Phloral, developed by researchers at the London School of Pharmacy, has been licensed to the UK firm Encap Drug Delivery.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.